Search company, investor...

Sword Diagnostics

sworddiagnostics.com

Founded Year

2004

Stage

Unattributed | Alive

Total Raised

$8.24M

Last Raised

$1.53M | 5 yrs ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+10 points in the past 30 days

About Sword Diagnostics

Sword Diagnostics is a life sciences company created in response to the needs of the research, pharmaceutical, and clinical communities. Although researchers are discovering thousands of biomarkers associated with both healthy and diseased-related biological processes, today's life science tools are unable to effectively measure, quantify, and determine the ultimate value of these biological markers. Sword Diagnostics' technology is directly aimed at making it easier to understand these newly emerging biomarkers, as well as extending the utility of existing diagnostics assays. Sword's mission is to provide the next-generation detection technology to life scientists, enabling them to continue advances in medical research, drug discovery and the provision of health care products and services.

Headquarters Location

3440 South Dearborn Street Suite 142-S

Chicago, Illinois, 60616,

United States

708-563-9166

Missing: Sword Diagnostics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Sword Diagnostics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Sword Diagnostics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sword Diagnostics is included in 4 Expert Collections, including Medical Devices.

M

Medical Devices

8,605 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

B

Biopharma Tech

838 items

H

Health IT

7,901 items

Sword Diagnostics Patents

Sword Diagnostics has filed 4 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/3/2015

12/18/2018

Spectroscopy, Molecular biology, Biotechnology, Analytical chemistry, Physical chemistry

Grant

Application Date

3/3/2015

Grant Date

12/18/2018

Title

Related Topics

Spectroscopy, Molecular biology, Biotechnology, Analytical chemistry, Physical chemistry

Status

Grant

Sword Diagnostics Frequently Asked Questions (FAQ)

  • When was Sword Diagnostics founded?

    Sword Diagnostics was founded in 2004.

  • Where is Sword Diagnostics's headquarters?

    Sword Diagnostics's headquarters is located at 3440 South Dearborn Street, Chicago.

  • What is Sword Diagnostics's latest funding round?

    Sword Diagnostics's latest funding round is Unattributed.

  • How much did Sword Diagnostics raise?

    Sword Diagnostics raised a total of $8.24M.

  • Who are the investors of Sword Diagnostics?

    Investors of Sword Diagnostics include NJTC Venture Fund, Keiretsu Forum, JumpStart NJ Angel Network, Launchpad Venture Group and Tech Council Ventures.

  • Who are Sword Diagnostics's competitors?

    Competitors of Sword Diagnostics include Gentronix Limited, Fluxion Biosciences, Echelon Biosciences, Phylogeny, Aushon BioSystems, NMS Group, Quanterix, Averica Discovery Services, IntelliCyt, Celsis International and 26 more.

Compare Sword Diagnostics to Competitors

Fluxion Biosciences Logo
Fluxion Biosciences

Fluxion Biosciences is a developer of precision solutions for life science research and diagnostics. Fluxion's liquid biopsy solutions are changing how cancer is detected and treated. Fluxion's pioneering liquid biopsy technologies include the IsoFlux CTC Liquid Biopsy System, ERASE-Seq ultra-sensitive variant caller, and the Spotlight 59 NGS Oncology Panel for cancer mutation detection from cell-free circulating tumor DNA. Fluxion's technologies are used globally by cancer centers developing new tests for early cancer detection and patient monitoring.

G
Genomic Solutions

The scientists at Genomic Solutions have a wealth of genomic, protein analysis and nano-liter dispensing application-based expertise that they would like to share with users. First select their area of research, followed by interest and then application, and finally, to the company's instrumentation which can help facilitate their research. Whether users are involved in the life science or biotechnology research community, the company's products will enable users to perform complex, high volume experiments at a lower cost and in less time than traditional techniques. You achieve rapid and less expensive drug discovery.

V
Vivonetics

Vivonetics a company created through Georgia Tech's VentureLab program. The company is developing applications for molecular beacon technology in life science research and drug discovery. Its initial focus is on probes to detect RNA in living cells.

P
PlexPress

PlexPress is a life science company doing work in gene expression analysis technology to advance biological science, drug discovery, crop science and diagnostics. PlexPress seeks to rapidly provide reliable information at low cost. Its products simultaneously measure multiple genes from multiple samples. PlexPress operates from Los Altos, California and Helsinki, Finland.

V
VivoPath

VivoPath is a preclinical screening company, offering the company's clients discovery and development services for in vivo testing. VivoPath aims to provide integrated in vivo studies led by established experts in drug development. Efficacy is established for animal models in the areas of metabolic disease, inflammation, neurodegenerative disease, and infectious diseases. Formulation screening is carried out to select the most appropriate delivery system for administration. Pharmacokinetic evaluation is carried out to assess exposure and bioavailability. Tolerability is assessed with evaluations of clinical signs, clinical chemistry and hematology. The resulting program aims to deliver the client an in vivo therapeutic index (TI) report on which to assess candidates for subsequent development. VivoPath can also help clients at any individual step in this preclinical screening process. VivoPath's commitment is to provide scientific expertise in in vivo drug discovery in order to increase productivity from research into drug development.

Echelon Biosciences Logo
Echelon Biosciences

Echelon Biosciences is a company that received a SBIR Phase I grant for a project entitled: Near Infrared Substrates for Imaging Autotaxin Activity In Vivo. Their project aims to synthesize ATXRed, an in vivo imaging agent that is specifically activated by the enzymatic activity of autotaxin. Autotaxin is an extracellular enzyme that generates the phospholipid growth factor lysophophatidic acid (LPA). LPA is involved in a variety of biological functions, such as angiogenesis, wound healing, brain development, immunological competence and the regulation of blood pressure. Both LPA and autotaxin have also been implicated in numerous diseases, especially metastatic cancer. Autotaxin was identified as one of the 40 most induced genes in aggressive breast cancer. The broader impacts of this research are the discovery and commercialization of tools that easily highlight specific biological pathways in living organisms. ATXRed will be welcomed by basic researchers in many fields associated with autotaxin and LPA. However, the utility extends beyond the basic research sphere. ATXRed smart probes could also aid pharmaceutical researchers searching for pharmacological inhibitors of autotaxin and LPA receptor agonists and antagonists. ATXRed would be a powerful tool in many rodent models of human cancer. In vivo autotaxin imaging probes could also aid in the clinic by helping to identify and monitor disease progression and treatment. Ultimately, ATXRed could help guide surgical resection of tumorstumors previously identified by the smart probe to have elevated autotaxin activity. In total, ATXRed probes have the potential to impact basic research, drug discovery and the clinic as a prime example of molecular medicine applied from bench to bedside.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.